In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a
share purchase programme under which the company will buy own shares for an
amount of up to DKK 50 million during 2009.

The programme is structured according to European Commission Regulation No
2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules,
for the purchase of own shares.

In the past week, since the issue of status announcement no. 50-09 of 28
September 2009, the following transactions have been made under NeuroSearch's
share purchase programme:

Accumulated share purchase / Number of shares / Average price (DKK) /
Transaction value (DKK)

28 Sept 2009 - - -
29 Sept 2009 - - -
30 Sept 2009 - - -
1 Oct 2009 2,244 147,50 330,990
2 Oct 2009 9,160 139,00 1,273,240
Total 11,404 140,67 1,604,230


With the purchased amount of shares as stated above, NeuroSearch now holds a
total of 260,034 treasury shares of DKK 20 nominal value each, corresponding to
1.51% of the total number of 17,237,830 issued shares in NeuroSearch A/S.

An amount of DKK 20,883,438 remains to be used under the share purchase
programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX
Copenhagen on Friday 2 October 2009, this corresponds to a maximum of 150,240
additional NeuroSearch shares to be bought under the programme.


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103



About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug
pipeline comprises eight clinical (Phase I-III) development programmes:
Huntexil™ (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK.
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.

fonds.51-09 - share purchase programme - 21th update - uk - final.pdf